Physician profile
Michael Baehr
NPI 1992771869
$1,683.03
in general payments reported to CMS, 2019-2025
21 companies · $18.09 in 2025
The $18.09 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $264 · 2020: $132 · 2021: $60.31 · 2022: $228 · 2023: $769 · 2024: $211 · 2025: $18.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $999.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $998.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $205.64 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $181.52 | 2022-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $172.31 | 2019-2023 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $165.67 | 2022-2024 | |
| Lilly USA, LLC | $146.52 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Ge Healthcare | $136.43 | 2024 | |
| Stryker Corporation | $103.86 | 2022 | |
| Pfizer INC. | $84.41 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $73.02 | 2019-2023 | Farxiga |
| Procept Biorobotics Corporation | $57.16 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.09 | 2023 | Xifaxan, Ibschek |
| Abbvie INC. | $42.30 | 2023 | Vraylar, Ubrelvy |
| Exact Sciences Corporation | $37.07 | 2023 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $36.77 | 2019 | |
| Idorsia Pharmaceuticals US INC | $34.08 | 2023-2024 | Quviviq |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $33.36 | 2019 | |
| Novartis Pharmaceuticals Corporation | $32.11 | 2022-2023 | |
| Amarin Pharma, INC. | $29.73 | 2020 | |
| Dexcom, INC. | $24.41 | 2023 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $21.98 | 2023 | Accrufer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Baehr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.